Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD)

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3

Prior research has shown that chamomile may be an effective, short-term anti-anxiety treatment. This study will examine the initial and long-term benefits of chamomile extract therapy for the prevention of recurrent anxiety disorder.

Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: No

• Men and women at least 18 years old (all races and ethnicity)

• DSM IV diagnosis of GAD as the primary anxiety disorder

• Baseline GAD-7 score ≥ 10

• Baseline CGI/S score at least 4

• Not taking anti-anxiety medication (e.g., Benzodiazepines, buspirone, antidepressants)

• Not taking antidepressant, mood stabilizer, or tranquilizer therapy for a prior DSM IV Axis I mood disorder that is in remission

• Able to understand and provide informed consent

• Able to participate in a 38-week study

United States
Depression Research Unit
Time Frame
Start Date: February 2010
Completion Date: June 2015
Target number of participants: 180
Experimental: Chamomile Extract
Pharmaceutical grade oral chamomile extract.
Placebo Comparator: Placebo
Pharmaceutical grade lactose monohydrate.
Related Therapeutic Areas
Leads: University of Pennsylvania

This content was sourced from clinicaltrials.gov

Similar Clinical Trials